Diagnosis and Treatment of Multiple Sclerosis

Диагностика и лечение рассеянного склероза
Alexander D Rae-Grant, Marisa McGinley, Carolyn H. Goldschmidt
2021-02-23

2017 McDonald Criteriaannualized relapse rateautoimmune thyroid diseasecerebrospinal fluid oligoclonal bandscladribinediagnosisdisease-modifying therapies (DMTs)fumaratesgadolinium-enhancing lesionsglatiramer acetateinterferonsmagnetic resonance imaging (MRI) T2 lesionsmonoclonal antibodiesmultiple sclerosisocrelizumabprimary progressive MSrelapsing-remitting MSsphingosine 1-phosphate receptor modulatorsteriflunomide
Importance: Multiple sclerosis (MS) is an autoimmune-mediated neurodegenerative disease of the central nervous system characterized by inflammatory demyelination with axonal transection. MS affects an estimated 900 000 people in the US. MS typically presents in young adults (mean age of onset, 20-30 years) and can lead to physical disability, cognitive impairment, and decreased quality of life. This review summarizes current evidence regarding diagnosis and treatment of MS. Observations: MS typically presents in young adults aged 20 to 30 years with unilateral optic neuritis, partial myelitis, sensory disturbances, or brainstem syndromes such as internuclear ophthalmoplegia developing over several days. The prevalence of MS worldwide ranges from 5 to 300 per 100 000 people and increases at higher latitudes. Overall life expectancy is less than in the general population (75.9 vs 83.4 years), and MS more commonly affects women (female to male sex distribution of nearly 3:1). Diagnosis is made based on a combination of signs and symptoms, radiographic findings (eg, magnetic resonance imaging [MRI] T2 lesions), and laboratory findings (eg, cerebrospinal fluid-specific oligoclonal bands), which are components of the 2017 McDonald Criteria. Nine classes of disease-modifying therapies (DMTs), with varying mechanisms of action and routes of administration, are available for relapsing-remitting MS, defined as relapses at onset with stable neurologic disability between episodes, and secondary progressive MS with activity, defined as steadily increasing neurologic disability following a relapsing course with evidence of ongoing inflammatory activity. These drugs include interferons, glatiramer acetate, teriflunomide, sphingosine 1-phosphate receptor modulators, fumarates, cladribine, and 3 types of monoclonal antibodies. One additional DMT, ocrelizumab, is approved for primary progressive MS. These DMTs reduce clinical relapses and MRI lesions (new T2 lesions, gadolinium-enhancing lesions). Efficacy rates of current DMTs, defined by reduction in annualized relapse rates compared with placebo or active comparators, range from 29%-68%. Adverse effects include infections, bradycardia, heart blocks, macular edema, infusion reactions, injection-site reactions, and secondary autoimmune adverse effects, such as autoimmune thyroid disease. Conclusions and Relevance: MS is characterized by physical disability, cognitive impairment, and other symptoms that affect quality of life. Treatment with DMT can reduce the annual relapse rate by 29% to 68% compared with placebo or active comparator.
1
Current DMTs reduce annualized relapse rates by 29%–68% versus placebo or active comparators but carry adverse effects including infections, cardiac effects, macular edema, infusion/injection reactions, and secondary autoimmune diseases.
2
Diagnosis uses the 2017 McDonald Criteria combining clinical signs, MRI T2 lesions, and CSF-specific oligoclonal bands.
3
Global MS prevalence ranges from 5 to 300 per 100,000 and increases at higher latitudes; women are affected nearly 3:1, and life expectancy is reduced (75.9 vs 83.4 years).
4
MS is an autoimmune-mediated neurodegenerative CNS disease causing inflammatory demyelination with axonal transection and affects an estimated 900,000 people in the US.
5
MS typically presents in young adults (mean age 20–30 years) with unilateral optic neuritis, partial myelitis, sensory disturbances, or brainstem syndromes developing over several days.
6
Nine classes of DMTs for relapsing-remitting and active secondary progressive MS (and ocrelizumab for primary progressive MS) reduce clinical relapses and MRI lesions.

Multiple sclerosis (MS) as a neurodegenerative autoimmune disease of the central nervous system

Diagnosis and treatment effectiveness of MS, including diagnostic criteria (clinical signs, MRI T2 lesions, CSF oligoclonal bands per 2017 McDonald Criteria) and efficacy/safety of disease-modifying therapies (reductions in annualized relapse rates, MRI lesion reduction, and adverse effects)

Publication Details
Publication Date
2021-02-23
Journal
Publisher
ISSN
Cited by
1196
Access Type
Author Information
Authors
Alexander D Rae-Grant
Marisa McGinley
Carolyn H. Goldschmidt
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%